The camelina plant, a source of cooking oil for ce
Chennai 19th January 2021: Metrohm India Private L
Vibrio parahaemolyticus is a marine bacterium that
Neuried, Germany – 19 January 2021 –The rapid
Drug firm Strides Pharma Science on Friday said it
A microplate or microtiter plate (spelled Microtit
New Delhi, Dec 30 (PTI) Drug firm Zydus Cadila on Wednesday said it has received approval from the Drug Controller General of India (DCGI) for Saroglitazar Mg, used for the treatment of non-alcoholic fatty liver disease (NAFLD), in the nation.
Zydus Cadila explained the prevalence of NAFLD in India is estimated to be nearly 25-30 percent of the overall population.
This NAFLD condition could progress to NASH, cirrhosis and liver failure.
It’s a large unmet medical need as there is currently no approved drug for the treatment of NAFLD and NASH anywhere in the world, Zydus Cadila said.
Pankaj Patel, the Chairman of Zydus Group, stated with Saroglitazar Mg, the company has managed to successfully provide an innovative medicine for dealing with chronic liver diseases like NAFLD and NASH and helping patients in leading healthier lives.
In March 2020, Saroglitazar Mg had received approval for the treatment of NASH. PTI SVK MR MR